Loading
Instead of hitting a tumour with the maximum dose until it stops working, adjust the dose to keep the tumour small and let drug-sensitive cells suppress resistant ones. Test this properly across several cancers.
Adaptive therapy, in which dosing is modulated on a tumour burden marker to maintain a stable population of sensitive cells, extended time to progression in a pilot of abiraterone in prostate cancer. It has not been tested at scale or outside prostate. A platform trial would run adaptive versus continuous dosing arms in prostate (PSA), ovarian (CA-125) and melanoma (ctDNA) simultaneously with a shared evolutionary modelling core.
Shares Moffitt Cancer Center, Wrong doses, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Ovarian cancer.
Shares Moffitt Cancer Center, Tumour heterogeneity and clonal evolution, Melanoma.
Shares Moffitt Cancer Center, Tumour heterogeneity and clonal evolution.
Shares Moffitt Cancer Center, Melanoma.
Shares Basket, umbrella, and platform trials, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares Wrong doses, Tumour heterogeneity and clonal evolution.
Shares Wrong doses, Prostate cancer.
Shares Moffitt Cancer Center, Melanoma.